Video

Dr. Seymour on the 4-Year Update of the MURANO Trial in CLL

Author(s):

John F. Seymour, MBBS, PhD
Conference|ASH Annual Meeting and Exposition

John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Centre, director of the integrated Haematology Department of the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, discusses the 4-year update of the phase III MURANO trial in chronic lymphocytic leukemia (CLL).

John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Centre, director of the integrated Haematology Department of the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, discusses the 4-year update of the phase III MURANO trial in chronic lymphocytic leukemia (CLL).

<<< View more from the 2019 ASH Annual Meeting

Related Videos
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Related Content
NX-5948 for R/R CLL/SLL | Image Credit: © Dr_Microbe - stock.adobe.com
November 21st 2024

EMA Grants PRIME Designation to NX-5948 for R/R CLL/SLL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

FDA
November 20th 2024

FDA Approves New Drug Labeling for Fludarabine Phosphate in CLL

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

Sebastian Kaulitzki – stock.adobe.com
November 14th 2024

2024 Updates in GI Cancer Feature FLOT Combinations, Restricted FDA Approvals by PD-L1 Expression, and More

CAR T Cells in R/R Non-Hodgkin Lymphoma | Image Credit: © Tatiana Shepleva - stock.adobe.com
November 14th 2024

Transposon-Based BAFF CAR T Cells Show Early Efficacy, Safety in R/R Non-Hodgkin Lymphoma